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A case of COVID-19 immediately after liver transplantation: 
Not only bad news
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COVID-19, the illness caused by the SARS-CoV-2 virus originated in December 2019 in Wuhan, China and has caused 
more 3,3 million cases and more than 230,000 deaths throughout the world, with 25,000 of them only in Spain, where 
the first case was diagnosed on January 31st, 2020. As COVID-19 is a “new” disease, we still do not have data 
on prognosis or treatment in transplant patients or on how to manage immunosuppression in this complex scenario. 
We present a case of COVID-19 diagnosed during the early postoperative period in a recipient whose liver trans-
plantation was performed on late March during the lockdown in Spain, with donor and recipient previously negative 
rRT-PCR to SARS-CoV-2. In the first post-operative week the patient suffered COVID-19 pneumonia that was treated 
with immunosuppression minimization, oral Hydroxycloroquine and Azithromycin with favorable outcome. The patient 
was discharged on POD 21 without complications. To date, few early post-liver transplantation SARS-CoV-2 infected 
recipients have been published, but only one was an early postoperative infection. In our case the outcome was favor-
able, even though it was an early post -liver transplantation COVID-19 in a frail patient. (Ann Hepatobiliary Pancreat 
Surg 2020;24:314-318)
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INTRODUCTION
The coronavirus disease-19 (COVID-19) originated in 
December 2019, in the city of Wuhan (Hubei, China) as 
an outbreak caused by a virus named “severe acute respi-
ratory syndrome coronavirus 2” (SARS-CoV-2). The 
World Health Organization (WHO) declared COVID-19 a 
pandemic on March 11, 2020. As of May 3rd, 2020, the 
disease has been reported in 215 countries all over the 
world with 3,349,786 confirmed cases and over 238,628 
deaths.1 In Spain, the first case was diagnosed on January 
31st, 2020, and to date, up to 217,466 cases have been 
diagnosed with 25,264 deaths reported.2 To date, Spain is 
the country with the second-highest number of confirmed 
COVID-19 cases.1
In general population, 20% of COVID-19 patients de-
velop severe illness requiring hospital admission. Moreover, 
5% of patients need intensive care support, with a re-
ported case fatality rate of 1-6% (11.6% in Spain).2,3 
Patients under chronic immunosuppression such as liver 
transplantation recipients (LT) may present atypical respi-
ratory infections, difficult to distinguish from other post-
operative infections.4 To date, few clinical experiences 
have been published on how SARS-CoV-2 affects im-
munosuppressed or transplant patients.5-7 On the other 
hand, there are some data among surgical patients with 
postoperative COVID-19 infection, 44.1% requiring Intensive 
Care Unit (ICU) with a mortality rate approaching 50%,8 
reflecting a much more higher ICU admission and mortal-
ity rates than non-surgical COVID19 patients.3 Lei et al.8 
suggest that surgery may accelerate and exacerbate dis-
ease progression of COVID-19.
To date, only one case of early postoperative COVID-19 
disease has been described in LT.9 We present a case of 
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Fig. 1. Chest radiography showing diffuse bilateral infiltrates.
COVID-19 diagnosed during the early postoperative peri-
od in a recipient whose LT was performed at the end of 
March during the lockdown in Spain. 
CASE
The liver recipient was a blood group A positive 52- 
year-old male, with decompensated alcoholic cirrhosis and 
severe portal hypertension (MELD 20, encephalopathy, 
ascites, hepatorenal syndrome type II with an preoperative 
estimated glomerular filtration rate [eGFR] of 52 ml/min), 
atrial fibrillation and a gastric by-pass surgery due to mor-
bid obesity performed 7 years ago (actual body mass in-
dex was 35). He had been hospitalized until 2 days before 
the transplant due to recurrent liver complications and, de-
spite not having fever or clinically evident infection, sur-
veillance nasopharyngeal and oropharyngeal swabs for 
SARS-CoV-2 RT-PCT were obtained but resulted negative.
The donor was a blood group 0 positive, 47-year-old 
man without any previous disease who died from intra-
cranial hemorrhage after a work-related accident. Following 
the current recommendations of the Spanish National 
Transplant Organization,10 the donor and next of kin were 
investigated for epidemiological risks or presence of clin-
ical symptoms compatible with COVID-19. Even though 
they showed no specific risks or symptoms, a nasophar-
yngeal and oropharyngeal swab SARS-CoV-2 real-time 
reverse-transcriptase–polymerase-chain-reaction (rRT-PCR) 
was performed, which was negative. The liver was procured 
by standard methods and appeared healthy upon retrieval.
The cold ischemia time was 283 minutes, the warm is-
chemia time was 25 minutes and the total surgery time 
was 225 minutes. All anastomoses were done in a stand-
ard way following a piggyback technique. The patient re-
quired 1 unit of packed red blood cells administered 
intraoperatively.
The patient received Basiliximab for induction therapy 
(day 0 and day 4) combined with Mycophenolate Mofetil 
(MMF), 1 g/12 hours and glucocorticoids (Prednisone 20 
mg per day), according to our protocol for patients with 
pretransplant renal dysfunction, with good postoperative 
graft function.11 On postoperative day (POD) 3, MMF was 
reduced to 500 mg/12 hours due to pancytopenia. At that 
point, pancytopenia was thought to be to be related with 
surgery and his previous cirrhosis. The patient showed an 
uneventful initial course, so he was discharged from the 
ICU on the following day, without any infectious or respi-
ratory symptoms. On POD 5 he presented with fever 
(38°C), dyspnea, hypoxia (89% on room air), and tachyp-
nea without respiratory distress. Supplemental oxygen via 
nasal cannula (2 liters/minute), antipyretic (Paracetamol 1 
g) and intravenous broad-spectrum antibiotic therapy (Mero-
penem 1 g/8 hours and Linezolid 600 mg/12 hours) were 
started. Blood cultures were negative, and chest radiog-
raphy showed diffuse bilateral infiltrates (Fig. 1). White 
blood cell count on peripheral blood was 4.9×103/ml with 
lymphopenia (0.4×103/ml) and with a platelet count of 
48×103/ml, with a high ferritin (783 ng/ml) and high 
D-dimers (16.200 ng/ml) levels. The lactate dehydrogen-
ase was normal (243 UI/L). Kidney (eGFR>90 ml/min) 
and liver graft function were normal. Considering the pa-
tient’s immunosuppression and symptoms, and the pan-
demic state at the end of March, (at that time 335 patients 
with confirmed COVID-19 infection were hospitalized at 
Cruces University Hospital),12 a committee of transplant 
surgeons, hepatologist and infectious diseases specialists, 
decided to develop a secure pathway for all the contacts, 
and to repeat a nasopharyngeal/oropharyngeal swab SARS- 
CoV-2 rRT-PCR to the patient, which was again negative. 
Two days after the chest radiography, we performed a CT 
on POD 7, but it did not show any characteristic images.
In spite of the patient’s clinical improvement, and due 
to the high clinical suspicion, the secure pathway was 
maintained and a new nasopharyngeal/oropharyngeal swab 
for SARS-CoV-2 rRT-PCR was performed 48 hours later, 
that turned out positive. We contacted the donor center 
in order to retrieve new samples from the donor to per-
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Fig. 2. Case report evolution. PR-TAC, prolonged released tacrolimus; D, day; LT, liver transplantation; POD, postoperative day.
form a SARS-CoV-2 serology, which were confirmed nega-
tive. Previous to start the treatment with oral Hydroxyclor-
oquine and Azithromycin our patient was evaluated by the 
cardiologist, without contraindication. That day we de-
cided to start treatment with oral Hydroxycloroquine (400 
mg/12 hours for the first 24 hours and then 200 mg/12 
hours) and Azithromycin (500 mg/24 hours the first 24 
hours and then 250 mg/24 hours).13 Graft showed pro-
gressive cholestatic dysfunction (gGT 484 U/L, ALP 634 
U/L and bilirubin 7.2 mg/dl) which was considered related 
to under immunosuppression so 0.05 mg/kg/day prolonged 
release Tacrolimus was introduced, in order to keep im-
munosuppression close to the lower range of our standard 
target levels for the initial posttransplant period (between 
4-6 ng/ml).11 The patient was moved to a COVID-19 spe-
cific ward. Meropenem and Linezolid were discontinued 
after 8 days. Patient’s general condition continued to 
improve. Nasopharyngeal/oropharyngeal swab for SARS- 
CoV-2 rRT-PCR performed on POD 14 turned out nega-
tive. Lymphopenia (2×103/ml), platelet count (252×103/ml), 
ferritin (469 ng/ml) and D-Dimers (4.240 ng/ml) levels 
progressively normalized. Graft function quickly returned 
to normal after several adjustments of triple immuno-
suppressive therapy. Hydroxycloroquine and Azithromycin 
were prescribed for 8 days and discontinued after the neg-
ative rRT-PCR. At the time the patient was diagnosed and 
treated only one negative SARS-CoV-2 rRT-PCR after 
treatment was the policy of the Spanish health ministry.
The patient was discharged on POD 21 without further 
complications (Fig. 2). 
DISCUSSION
Severe acute respiratory syndrome coronavirus (SARS- 
CoV) and Middle East respiratory syndrome coronavirus 
(MERS-CoV) were reported in transplant recipients dur-
ing prior outbreaks of these viruses.14 Although it is not 
yet known if immunosuppression is a risk factor for more 
severe disease, the transplant community eagerly awaits 
more studies in this patient population.6 The first two re-
ported cases of solid organ transplantation (SOT) with 
COVID-19 were two heart transplant recipients from the 
city of Wuhan (Hubei, China).15 To date, few clinical cas-
es of LT with COVID-198,9,16,17 and three series from Italy 
and USA with small number7,18,19 have been published and 
only one was an early infection just after LT.8 Recently, 
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the first COVID-19 related death after LT has been reported.17 
In our case, even though it was an early post-LT COVID- 
19 in a frail patient, a favorable outcome was observed. 
As SARS-CoV-2 rt-PCR was negative for both donor and 
recipient, we decided to initiate intravenous broad-spec-
trum antibiotic therapy. The MMF dose had already been 
reduced due to pancytopenia. Due to the pandemic state 
at our country and center, and the high suspicion derived 
from the clinical status compatible with a stage IIa 
(moderate) pulmonary COVID-19 involvement,20 a new 
nasopharyngeal/oropharyngeal swab SARS-CoV-2 rRT-PCR 
was performed 48 hours later and COVID-19 was 
confirmed. Hydroxycloroquine and Azithromycin were im-
mediately added while previous antibiotic therapy was 
progressively withdrawn. 
Our patient showed symptoms on POD 5, in accord-
ance with the findings by Lei et al.8 who suggest that pa-
tients may develop COVID-19 symptoms after general 
surgery procedures within a shorter period of time 
(between 2 and 6 days) than the conventional COVID- 19 
patients. The secure pathway was maintained during all 
the postoperative period. The was no clinical evidence of 
SARS-CoV-2 infection in the transplantion group which 
includes surgeons, anesthetists, hepatologists, nurses and 
all manpower in direct contact with the donor or the re-
cipient’s family. Rt-PCR for SARS-CoV-2 has high sensi-
tivity and specificity but these tests can show false 
negatives. Usually these are due to the sample being in-
sufficient or unrepresentative, taken too early or too late 
in the course of the disease, or degraded during transport 
or handling. In negative cases in which suspicion or 
symptoms persist, it is recommended to repeat the Rt-PCR 
within a few days.20 The theory supporting a shorter in-
cubation period may be difficult to apply here, because 
it is unknown whether the patient was in incubation peri-
od upon admission or if this was acquired during his hos-
pital stay and showed two false negative Rt-PCR tests. It 
seems more clear that it is not a donor to recipient trans-
mission of COVID-19 as the donor and next of kin were 
investigated for epidemiological risks or presence of clin-
ical symptoms compatible without suspicion, the Rt-PCR 
and the serology were also negative. 
It is known that in these initial stages, symptoms can 
be mild and non-specific; however, chest imaging may re-
veal bilateral infiltrates or ground glass opacities as, in 
our case.21 Currently, there is no strong evidence from 
controlled clinical trials to recommend a specific treat-
ment for the SARS-CoV-2 coronavirus or the manage-
ment of immunosuppression in LT in patients with con-
firmed COVID-19. The Spanish Society of Liver Trans-
plantation guidelines recommend a reduction in MMF 
dose and maintenance of calcineurin inhibitor levels to the 
desired range in recipients with Stage I or IIa COVID-19.13 
It is known that immunosuppressed patients have higher 
risk of developing infections; however, it is also possible 
that immunosuppressants could downregulate the delete-
rious inflammatory cascade characteristic of Stage III of 
this viral infection.6 Therefore, it may be possible that 
maintaining immunosuppressive treatment could help 
overcome the immunoreactive phase of the disease. In our 
case, we followed our standard immunosuppression policy 
for recipients with renal dysfunction: induction therapy, 
prednisone, MMF and delayed/reduced once-daily Tacro-
limus.11 MMF was already reduced when COVID-19 was 
suspected, so we initially maintained Tacrolimus levels in 
the lower range; later Tacrolimus was progressively in-
creased as needed, without clear impact on COVID19 
evolution. Our local policy is to consider liver biopsy only 
when cholestatic dysfunction continues, after achieving ta-
crolimus levels within therapeutic range and other poten-
tial causes have been rule out. Regarding specific thera-
pies for COVID-19 we followed the recommendations of 
the Spanish Society of Liver Transplantation and decided 
not to use Lopinavir/Ritonavir (very weak evidence of ef-
ficacy and significant drug interactions) but added oral 
Hydroxycloroquine and Azithromycin, which the risk/ben-
efit ratio was considered acceptable despite the absence 
of clear evidence.13 Clinical trials, mostly for Stage III 
COVID-19 infection, are currently evaluating potential 
therapies including Remdesivir, which has been pre-
viously administered to Ebola virus patients, and others 
such as Tocilizumab.22
In Spain, universal screening (through nasopharyngeal 
and oropharyngeal rRT-PCR) is now mandatory for all 
donors across the country. In the Basque Country, with 
193.04 COVID-19 cases per million population,2 we 
should balance the risks of postponing a livesaving trans-
plant with the rationing of healthcare resources and the 
high risk of postoperative infection even when secure 
pathways are organized. In this pandemic scenario, a 
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phased approach to decrease transplant activity has been 
recommended.23 In Spain a dramatic decrease in organ 
donation has been observed: from a mean of 15-18.6 do-
nors per day in the first months of 2020 to a mean of 
0.3-1.4 donors per day during the lockdown period.10
In conclusion, although liver recipients could be consid-
ered as potentially high-risk patients, favorable outcomes 
could be achieved even in case of postoperative COVID- 
19 infection, provided that a quick diagnosis is made.
The fact that immunosuppressive state could be pro-
tective in severe COVID-19, as proposed by some au-
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